TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 3.4% – Should You Sell?

Shares of TransCode Therapeutics Inc. (NASDAQ:RNAZ) dropped 3.4% during trading on Tuesday . The company traded as low as $8.93 and last traded at $8.98. Approximately 7,321 shares traded hands during trading, a decline of 95% from the average daily volume of 136,176 shares. The stock had previously closed at $9.30.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $280.00.

TransCode Therapeutics Stock Performance

The firm has a market capitalization of $8.26 million, a P/E ratio of -0.33 and a beta of 1.55. The firm has a 50 day simple moving average of $8.62 and a two-hundred day simple moving average of $10.19.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its earnings results on Friday, November 14th. The company reported ($5.49) EPS for the quarter, beating the consensus estimate of ($9.24) by $3.75. Sell-side analysts anticipate that TransCode Therapeutics Inc. will post -4.76 earnings per share for the current year.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.